AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Performance Of Flu Vaccine Needle-Free System Equal To Injection.(Brief Article)
2001 AUG 22 - (NewsRx.com & NewsRx.net) --
Bioject Medical Technologies, Inc. (BJCT) announced the results of a study investigating the delivery of the influenza vaccine with the Biojector 2000 needle-free injection system in elderly patients.
The study compared the immune response of influenza vaccine delivered by the standard route, needle and syringe, to that of influenza vaccine delivered by the Biojector 2000. Patients in both groups received intramuscular injections of 0.5 mL of vaccine. The results of the study confirmed equivalence between the two delivery routes. Also, the Biojector group exhibited encouraging trends toward improved immunogenicity for at least one of the three influenza strains that make up the trivalent vaccine, but these trends were not statistically significant.
Patient enrollment in the study was significantly lower than expected because of delays related to a worldwide shortage of vaccine. The study was conducted at the Mayo Clinic, in Rochester, Minnesota, by Dr. Gregory Poland, a member of the U.S. National Institutes of Health's (NIH) Advisory Committee on immunization practices. Complications related to influenza infection of seniors results in approximately 20,000 deaths each year in the United States.
"An improved delivery system for the influenza vaccine would be extremely valuable for elderly patients, for whom influenza is a significant risk," said Jim O'Shea, Bioject. "The results of this study are encouraging and we will continue to make vaccine delivery a high priority in our internal research and development initiatives. We look forward to forming a strategic partnership with a leading vaccine company interested in utilizing our technology to improve the comfort, patient ...
- Vical to Manufacture DNA Vaccines for NIAID/NIH Vaccine Research Center.
- Press release article from: PR Newswire May 12, 2003 700+ words
...contract to manufacture bulk DNA vaccines for the Vaccine Research Center (VRC), part of the National Institute of Allergy and...are delighted to broaden our relationship with the Vaccine Research Center," said Vijay B. Samant, Vical's President and Chief...
- Encouraging immune response seen in ''Prime/Boost'' Phase I HIV vaccine study;...
- News wire article from: Asia Africa Intelligence Wire September 7, 2005 700+ words
...developed by GenVec and the Vaccine Research Center (VRC) of the National Institute...between GenVec and the NIAID Vaccine Research Center, and was constructed using GenVec...inserts developed by the NIAID Vaccine Research Center. GenVec produced the related clinical...
- Encouraging Immune Response Seen in ''Prime/Boost'' Phase I HIV Vaccine Study;...
- Press release article from: Business Wire September 7, 2005 700+ words
...developed by GenVec and the Vaccine Research Center (VRC) of the National Institute...between GenVec and the NIAID Vaccine Research Center, and was constructed using GenVec...inserts developed by the NIAID Vaccine Research Center. GenVec produced the related clinical...
- Vical to manufacture DNA vaccines for NIAID/NIH Vaccine Research Center.
- News wire article from: Asia Africa Intelligence Wire May 12, 2003 700+ words
...Chemical Business NewsBase - Press Release) Vical Inc announced a contract to manufacture bulk DNA vaccines for the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. In support...
- Epimmune awarded NIH vaccine contract.
- Newspaper article from: Vector & Zoonosis Week November 11, 2002 700+ words
...for a total potential value of $3.5 million over 5 years. Epimmune will work with investigators at the Naval Medical Research Center (NMRC) on the program. Under previous NIH sponsorship and in collaboration with the NMRC, Epimmune identified both cytotoxic...
- NIH research center to further scientists' AIDS study.(Government...
- Magazine article from: Washington Business Journal WILMOT-WEIDMAN, KIMBERLY April 27, 2001 700+ words
...square-foot Dale and Betty Bumpers Vaccine Research Center (VRC), on the NIH's campus in Bethesda...the surrounding residential areas." * CLOSE UP NIH VACCINE RESEARCH CENTER * Size: 86,000 square feet * Value: $32 million...
- NIH to conduct human trial of experimental SARS vaccine.(National Institutes of...
- Magazine article from: Emergency Preparedness News December 14, 2004 700+ words
...Scientists at the National Institutes of Health (NIH) Vaccine Research Center will test the experimental vaccine on 10 healthy...killed 774 worldwide. Contact: NIH's Vaccine Research Center, (866) 833-LIFE, www.nih.gov.
- AlphaVax Announces a New NIH Vaccine Grant for Influenza.
- Press release article from: PR Newswire April 18, 2005 700+ words
RESEARCH TRIANGLE PARK, N.C., April 18 /PRNewswire/ -- AlphaVax announced today that it has received a significant new vaccine development grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the U.S. Department of
- AlphaVax announces a new NIH vaccine grant for influenza.
- News wire article from: Asia Africa Intelligence Wire April 18, 2005 700+ words
(From Chemical Business NewsBase - Press Release) AlphaVax has received a significant new vaccine development grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), an agency of the US Department of Health and Human Services. The new award
- Lipid Sciences Receives STTR Research Grant From National Institutes of Health...
- Press release article from: PR Newswire March 25, 2004 700+ words
Lipid Sciences, Inc. announced today that it is the recipient of a STTR (Small Business Technology Transfer) grant awarded by the NIH (National Institutes of Health) for a Virion Solvent Treatment for SARS (Severe Acute Respiratory Syndrome). The overall goal of this STTR grant is for Lipid
Source: HighBeam Research, Performance Of Flu Vaccine Needle-Free System Equal To...